Breakthrough in Triple-Negative Breast Cancer: Targeting EZH2 to Halt Metastasis Triple-negative breast cancer (TNBC) remains one of the most aggressive and hard-to-treat forms of breast cancer. A new preclinical study from Weill Cornell Medicine proposes a surprising and hopeful strategy: inhibiting an enzyme called EZH2 to prevent cancer cells from disseminating to distant organs by…